Cladribine (Mavenclad)
What to know about Cladribine — also sold as Mavenclad, CLADRITAB, Leustatin, Litak: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
Cladribine (brand names: Mavenclad, CLADRITAB, Leustatin, Litak) is classified as Moderate risk (3 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Potent immunosuppressive agent with significant infection risk and blood disorder potential.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Moderate (3 points)
- Recommended maximum duration: 365 days
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
Potent immunosuppressive agent with significant infection risk and blood disorder potential.
How Cladribine is regulated
Cladribine is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Check this medication against your full medication list
Run a full risk assessment including Cladribine interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.